 |
12 Products |  |
51 Diseases | | 12 Products |
|
10 Trials |  |
1329 News |  |
| «12...56789101112131415...1617» |
- | Copegus (ribavirin) / Bausch Health, Olysio (simeprevir) / J&J, Medivir, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Journal: No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk. (Pubmed Central) - Apr 11, 2019
There are no significant differences between DAA regimens in HCC risk after antiviral treatment. This suggests that DAAs do not have direct carcinogenic effects as it would be unlikely that different DAAs would have identical carcinogenic effects.
- | Copegus (ribavirin) / Bausch Health, Daklinza (daclatasvir) / BMS
Journal: Long-term follow-up of ribavirin-free DAA-based treatment in HCV-recurrence after orthotopic liver transplantation. (Pubmed Central) - Apr 10, 2019
RBV-free DAA-combinations for the treatment of HCV-recurrence after OLT are highly efficacious and well tolerated. Our long-term data show that viral eradication is durable but not necessarily translated into beneficial long-term clinical outcome.
- | Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer Internacional, Galen, Medivir
Review, Journal: Inhaled Loxapine for the Management of Acute Agitation in Bipolar Disorder and Schizophrenia: Expert Review and Commentary in an Era of Change. (Pubmed Central) - Apr 7, 2019
Emerging data have indicated the potential for inhaled loxapine as a self-administered agent for use in the community setting without the direct supervision of a healthcare professional. We discuss the evolving treatment paradigm and the place of inhaled medications for acutely agitated patients both within and outside the emergency and hospital setting.
- | Copegus (ribavirin) / Bausch Health, Olysio (simeprevir) / J&J, Medivir
Clinical, Journal: Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function. (Pubmed Central) - Apr 5, 2019
SOF-based regimens resulted in high SVR12 rates in patients with moderately impaired renal function. During therapy, HCV patients with CKD should be carefully monitored for worsening renal function.
- paritaprevir/ritonavir (ABT-450/r) / AbbVie
The comparison of hepatitis C treatment outcomes with direct acting antivirals between people who inject drugs (PWID) and non-PWID: results from a national survey in Slovenia () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_1144;
Our results confirm excellent SVR rates of DAAs in real-life setting with better results achieved in non-PWID compared to PWID. However, excluding those with premature treatment discontinuation for unknown reasons and the lack of FU12, the SVR rates were comparable between the two groups.
- | Olysio (simeprevir) / J&J, Medivir
Clinical, Journal: VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS. (Pubmed Central) - Apr 3, 2019
However, excluding those with premature treatment discontinuation for unknown reasons and the lack of FU12, the SVR rates were comparable between the two groups. In our real-life population the prevalence of RASs was high, especially in NS3 and NS5A and in those treated with suitable DAA regimens.
- | Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie, Daklinza (daclatasvir) / BMS
Clinical, Journal: Efficacy of Direct-acting Antivirals to Improve Clinical Condition, Fibrosis, and Liver Function in Liver Transplant Recipients Infected by Hepatitis C. (Pubmed Central) - Mar 27, 2019
In our real-life population the prevalence of RASs was high, especially in NS3 and NS5A and in those treated with suitable DAA regimens. DAAs were used successfully in the treatment of hepatitis C after orthotopic liver transplantation and resulted in significant improvement in liver function as measured by MELD score, fibrosis level, and cirrhotic clinical condition, even in patients with very advanced disease.
- | Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer Internacional, Galen, Medivir
Clinical, Journal: PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. (Pubmed Central) - Mar 25, 2019
There were no safety issues. Inhaled loxapine reduced agitation faster than IM aripiprazole, supporting its use as a first-line option for managing acute agitation in patients with schizophrenia or bipolar disorder.
- | Clinical, Journal: Short Duration AL-335, Odalasvir, With/Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis. (Pubmed Central) - Mar 25, 2019
In treatment-naïve subjects without cirrhosis, AL-335 + odalasvir + simeprevir for 6-8 weeks was generally safe and highly efficacious against HCV GT1. However, inadequate efficacy was observed for the 2-DAA regimen in GT1-infected subjects and the 3-DAA regimen in GT3-infected subjects.
- | AL-335 / J&J, Medivir
Clinical, PK/PD data, Journal: Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects. (Pubmed Central) - Mar 21, 2019
AL-335 was well tolerated when administered as single and multiple doses, with an acceptable pharmacokinetic profile. The drug also demonstrated potent antiviral activity in HCV GT1-4-infected subjects, including GT1-infected subjects with cirrhosis.
- | birinapant (IGM-9427) / IGM Biosciences
Enrollment open: Birinapant and Intensity Modulated Re-Irradiation Therapy for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 21, 2019
P1, N=34, Recruiting, Sponsor: National Cancer Institute (NCI)
The drug also demonstrated potent antiviral activity in HCV GT1-4-infected subjects, including GT1-infected subjects with cirrhosis. Not yet recruiting --> Recruiting
- | Olysio (simeprevir) / J&J, Medivir
Trial completion: Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure (clinicaltrials.gov) - Mar 19, 2019
P=N/A, N=40, Completed, Sponsor: Assiut University
Not yet recruiting --> Recruiting Recruiting --> Completed
- | remetinostat (SHP-141) / Medivir
New P2 trial: Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC) (clinicaltrials.gov) - Mar 15, 2019
P2, N=30, Not yet recruiting, Sponsor: Kavita Sarin
- | Pegasys (pegylated interferon α -2a) / Roche, Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir
Trial completion date, Trial primary completion date: SWITCH-1: Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Feb 28, 2019
P2, N=160, Recruiting, Sponsor: Humanity and Health Research Centre
Recruiting --> Completed Trial completion date: Mar 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Oct 2020
- | birinapant (IGM-9427) / IGM Biosciences
New P1 trial: Birinapant and Intensity Modulated Re-Irradiation Therapy for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 18, 2019
P1, N=34, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Olysio (simeprevir) / J&J, Medivir
Trial completion date, Trial primary completion date: Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis (clinicaltrials.gov) - Jan 17, 2019
P3, N=9, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial completion date: Mar 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Oct 2020 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | birinapant (IGM-9427) / IGM Biosciences
New P1 trial, Tumor mutational burden: Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 15, 2019
P1, N=34, Recruiting, Sponsor: National Cancer Institute (NCI)
- |||| fostroxacitabine bralpamide (MIV-818) / Medivir
New P1/2 trial: A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations (clinicaltrials.gov) - Dec 20, 2018
P1/2, N=102, Recruiting, Sponsor: Medivir
- | Olysio (simeprevir) / J&J, Medivir
Trial completion date, Trial primary completion date: Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure (clinicaltrials.gov) - Oct 9, 2018
P=N/A, N=50, Recruiting, Sponsor: Assiut University
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Sep 2018 --> Jan 2019 | Trial primary completion date: Jun 2018 --> Jan 2019
- | Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
Trial completion date, Trial primary completion date: Phase IV to Evaluate the Safety of Self-administered ADASUVE (clinicaltrials.gov) - Aug 21, 2018
P4, N=500, Recruiting, Sponsor: Ferrer Internacional S.A.
Trial completion date: Sep 2018 --> Jan 2019 | Trial primary completion date: Jun 2018 --> Jan 2019 Trial completion date: Mar 2018 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Aug 2019
- | Olysio (simeprevir) / J&J, Medivir
Clinical, Journal: Efficacy and Safety of Simeprevir and Sofosbuvir With and Without Ribavirin in Subjects With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant: The Randomized GALAXY Study. (Pubmed Central) - Aug 17, 2018
P2
Simeprevir exposure was increased relative to the non-transplant setting, but not considered clinically relevant. Simeprevir+sofosbuvir treatment, with or without ribavirin, was efficacious and well tolerated (ClinicalTrials.
- | birinapant (IGM-9427) / IGM Biosciences
Enrollment change, Trial withdrawal, Combination therapy: Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 16, 2018
P1/2, N=0, Withdrawn, Sponsor: Jonsson Comprehensive Cancer Center
Simeprevir+sofosbuvir treatment, with or without ribavirin, was efficacious and well tolerated (ClinicalTrials. N=17 --> 0 | Not yet recruiting --> Withdrawn
- | Trial completion, Enrollment change: A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir (clinicaltrials.gov) - Jul 24, 2018
P2a, N=161, Completed, Sponsor: Alios Biopharma Inc.
N=17 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | N=320 --> 161
- || MIV 710 / Medivir, MIV-711 / Medivir
New P1 trial: A Bioavailability Study of MIV-711 Oral Formulations in Healthy Volunteers (clinicaltrials.gov) - Jul 15, 2018
P1, N=18, Completed, Sponsor: Medivir
- | remetinostat (SHP-141) / Medivir
Enrollment open: Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer (clinicaltrials.gov) - Jul 12, 2018
P2, N=30, Recruiting, Sponsor: Kavita Sarin
Active, not recruiting --> Completed | N=320 --> 161 Not yet recruiting --> Recruiting
- | Olysio (simeprevir) / J&J, Medivir
Trial completion, Trial completion date: An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease (clinicaltrials.gov) - Jul 12, 2018
P2, N=40, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2018
- || Trial completion: A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive (clinicaltrials.gov) - Jun 18, 2018
P2a, N=33, Completed, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2018 Active, not recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir
New trial: Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure (clinicaltrials.gov) - Jun 8, 2018
P=N/A, N=50, Recruiting, Sponsor: Assiut University
- | Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
New trial: Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder (clinicaltrials.gov) - Jun 3, 2018
P=N/A, N=10000, Recruiting, Sponsor: Galen Limited
- | Trial completion, Enrollment change: Impact of Antiviral Therapy on Gastroesophageal Varices. (clinicaltrials.gov) - May 30, 2018
P=N/A, N=237, Completed, Sponsor: Parc de Salut Mar
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=374 --> 237
- Olysio (simeprevir) / J&J, Medivir
Trial completion date: An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease (clinicaltrials.gov) - Apr 25, 2018
P2, N=40, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | N=374 --> 237 Trial completion date: Mar 2020 --> Dec 2019
- | birinapant (TL 32711) / Medivir
Biomarker, PK/PD data, Preclinical, Journal, IO biomarker: Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis. (Pubmed Central) - Apr 24, 2018
Clinical feasibility was established using formalin-fixed, paraffin-embedded biopsies from a canine cancer clinical trial; γH2AX/CC3 colocalization analysis revealed apoptosis induction by two novel indenoisoquinoline topoisomerase I inhibitors, which was consistent with pathologist-assessed apoptosis and reduction of tumor volume. This assay is ready for use in clinical trials to elucidate the mechanism of action of investigational agents and combination regimens intended to inflict DNA damage, apoptotic cell death, or both.
- | Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Head-to-Head: Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation (clinicaltrials.gov) - Apr 6, 2018
P4, N=2, Terminated, Sponsor: University of Arkansas
This assay is ready for use in clinical trials to elucidate the mechanism of action of investigational agents and combination regimens intended to inflict DNA damage, apoptotic cell death, or both. N=140 --> 2 | Trial completion date: Aug 2019 --> Apr 2018 | Recruiting --> Terminated | Trial primary completion date: Aug 2019 --> Apr 2018; Sponsor Withdrawal
- Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection (clinicaltrials.gov) - Mar 27, 2018
P3, N=24, Terminated, Sponsor: Janssen Research & Development, LLC
N=140 --> 2 | Trial completion date: Aug 2019 --> Apr 2018 | Recruiting --> Terminated | Trial primary completion date: Aug 2019 --> Apr 2018; Sponsor Withdrawal N=54 --> 24 | Trial completion date: Jan 2022 --> Feb 2018 | Recruiting --> Terminated | Trial primary completion date: Oct 2020 --> Feb 2018; Recruitment prematurely stopped based on decision to stop HPC program (not due to safety or efficacy results) + On 31 Jan 2018 decision to stop the study
- | Pegasys (pegylated interferon α -2a) / Roche, Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir
Trial completion date, Trial primary completion date: SWITCH-1: Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Mar 19, 2018
P2, N=160, Recruiting, Sponsor: Humanity and Health Research Centre
N=54 --> 24 | Trial completion date: Jan 2022 --> Feb 2018 | Recruiting --> Terminated | Trial primary completion date: Oct 2020 --> Feb 2018; Recruitment prematurely stopped based on decision to stop HPC program (not due to safety or efficacy results) + On 31 Jan 2018 decision to stop the study Trial completion date: Dec 2017 --> Mar 2019 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
Clinical, Journal: An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. (Pubmed Central) - Mar 9, 2018
Acquisition of HER2T798I upon development of resistance to neratinib in a breast cancer with an initial activating HER2 mutation suggests HER2L869R is a driver mutation. HER2T798I-mediated neratinib resistance may be overcome by other irreversible HER2 inhibitors like afatinib.
- | Sovaldi (sofosbuvir) / Gilead
Trial completion, Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection (clinicaltrials.gov) - Mar 8, 2018
P4, N=10000, Completed, Sponsor: Tanta University
HER2T798I-mediated neratinib resistance may be overcome by other irreversible HER2 inhibitors like afatinib. Recruiting --> Completed | N=6000 --> 10000 | Trial completion date: Dec 2018 --> Mar 2018 | Initiation date: Dec 2016 --> Jan 2015 | Trial primary completion date: Dec 2018 --> Jan 2018
- | birinapant (IGM-9427) / IGM Biosciences
Trial initiation date, Combination therapy: Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Mar 3, 2018
P1/2, N=17, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Recruiting --> Completed | N=6000 --> 10000 | Trial completion date: Dec 2018 --> Mar 2018 | Initiation date: Dec 2016 --> Jan 2015 | Trial primary completion date: Dec 2018 --> Jan 2018 Initiation date: Feb 2018 --> Apr 2018
- | Trial completion date, Trial initiation date, Trial primary completion date: A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive (clinicaltrials.gov) - Mar 3, 2018
P2a, N=33, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Initiation date: Feb 2018 --> Apr 2018 Trial completion date: May 2018 --> May 2018 | Initiation date: Jan 2017 --> Dec 2016 | Trial primary completion date: May 2018 --> May 2018
- | remetinostat (SHP-141) / Medivir
Trial initiation date, Trial primary completion date: Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer (clinicaltrials.gov) - Jan 23, 2018
P2, N=30, Not yet recruiting, Sponsor: Kavita Sarin
Trial completion date: May 2018 --> May 2018 | Initiation date: Jan 2017 --> Dec 2016 | Trial primary completion date: May 2018 --> May 2018 Initiation date: Jan 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jun 2019
- Olysio (simeprevir) / J&J, Medivir
Trial primary completion date: Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis (clinicaltrials.gov) - Jan 17, 2018
P3, N=9, Active, not recruiting, Sponsor: University of Colorado, Denver
Initiation date: Jan 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jun 2019 Trial primary completion date: Dec 2017 --> Dec 2018
- | MIV 710 / Medivir, MIV-711 / Medivir
Trial completion: A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients (clinicaltrials.gov) - Dec 28, 2017
P2, N=50, Completed, Sponsor: Medivir
Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed
- Enrollment change, Trial termination, Trial primary completion date: Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC) (clinicaltrials.gov) - Dec 22, 2017
P1, N=72, Terminated, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed N=120 --> 72 | Recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Apr 2017; Decision to discontinue development of investigational Hep C treatment regimen JNJ-4178: 3 direct acting antivirals - AL-335, ODV & SMV.
- | adafosbuvir (AL-335) / J&J, Medivir
Trial completion, Enrollment change, Trial primary completion date: A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335 (clinicaltrials.gov) - Dec 20, 2017
P1, N=24, Completed, Sponsor: Janssen Research & Development, LLC
N=120 --> 72 | Recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Apr 2017; Decision to discontinue development of investigational Hep C treatment regimen JNJ-4178: 3 direct acting antivirals - AL-335, ODV & SMV. Recruiting --> Completed | N=32 --> 24 | Trial primary completion date: Mar 2017 --> Aug 2017
- Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
Phase classification: ADASUVE-Lorazepam Drug-Drug Interaction (clinicaltrials.gov) - Dec 13, 2017
P4, N=22, Completed, Sponsor: Alexza Pharmaceuticals, Inc.
Recruiting --> Completed | N=32 --> 24 | Trial primary completion date: Mar 2017 --> Aug 2017 Phase classification: P1 --> P4
- | birinapant (IGM-9427) / IGM Biosciences
Trial primary completion date, Combination therapy: Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Dec 7, 2017
P1/2, N=17, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Phase classification: P1 --> P4 Trial primary completion date: Nov 2019 --> Feb 2020
- |||| Trial completion: Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection (clinicaltrials.gov) - Dec 5, 2017
P2b, N=365, Completed, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Nov 2019 --> Feb 2020 Active, not recruiting --> Completed
- Trial primary completion date: A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive (clinicaltrials.gov) - Nov 21, 2017
P2a, N=33, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed Trial primary completion date: Oct 2017 --> May 2018
- | birinapant (IGM-9427) / IGM Biosciences
Phase classification, Enrollment change, Trial initiation date, Trial primary completion date, Combination therapy: Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Nov 20, 2017
P1/2, N=17, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial primary completion date: Oct 2017 --> May 2018 Phase classification: P2 --> P1/2 | N=34 --> 17 | Initiation date: Jan 2017 --> Dec 2017 | Trial primary completion date: Jul 2019 --> Nov 2019
- | Sovaldi (sofosbuvir) / Gilead
Enrollment change: Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection (clinicaltrials.gov) - Nov 14, 2017
P4, N=6000, Recruiting, Sponsor: Tanta University
Phase classification: P2 --> P1/2 | N=34 --> 17 | Initiation date: Jan 2017 --> Dec 2017 | Trial primary completion date: Jul 2019 --> Nov 2019 N=1000 --> 6000